<DOC>
	<DOCNO>NCT02123290</DOCNO>
	<brief_summary>This Proof-of-concept / Phase IIa , open label study examine efficacy DSM265 uncomplicated Plasmodium vivax Plasmodium falciparum blood-stage malaria adult patient . A minimum two cohort ( 20 patient ) maximum 6 cohort ( 60 patient , 3 dose level ) test . The start dose DSM265 first P. vivax P. falciparum cohorts 400 mg . This dose expect show complete clearance parasite microscopy Day 7 decrease recrudescence rate assess Day 14 ( success criterion dose de-escalation continuation study ) .</brief_summary>
	<brief_title>DSM265 Phase IIa Investigation Treating Plasmodium Falciparum Vivax</brief_title>
	<detailed_description />
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Malaria , Falciparum</mesh_term>
	<mesh_term>Malaria , Vivax</mesh_term>
	<criteria>Body weight 45kg 90kg Monoinfection P. falciparum P. vivax confirm : 1 . Fever , history fever previous 24 hour , 2 . Microscopically confirm parasite infection : 1,000 35,000 asexual parasite count/ÂµL blood Written inform consent Able swallow oral medication Able willing participate comply study requirement Agree hospitalisation least 72 hour malarial parasite detect microscopy 2 consecutive occasion Agree return clinic Day 5 ( addition study day ) , Day 3 malarial parasite fall level detection least two consecutive occasion . If long sign symptom malaria available every 34 day blood sample microscopy Quantitative Polymerase Chain Reaction , rehospitalisation standard treatment event level detectable Signs symptom severe / complicate malaria accord World Health Organisation Criteria 2010 Mixed Plasmodium infection Severe vomiting , ( three time 24 hour prior inclusion ) inability tolerate oral treatment , severe diarrhoea Presence serious chronic clinical condition require hospitalisation Severe malnutrition Known history evidence clinically significant disorder cardiovascular ( include arrhythmia , QTcB QTcF interval great equal 450 msec , personal family history long QT syndrome , PR interval &gt; 200msec ; degree heart block ) , respiratory ( include active tuberculosis ) , history jaundice , hepatic , renal , gastrointestinal , immunological , neurological ( include auditory ) , endocrine include type diabetes mellitus ( control ) , diabetes insipidus , uncontrolled hypo hyperthyroidism , endocrine reproductive disorder require concurrent medication , disorder adrenal function , infectious condition minor skin soft tissue infection confirm low urinary tract infection , malignancy , psychiatric , history convulsion neurological psychiatric abnormality ; disorder condition may render patient unfit participation place him/her increase risk Known active Hepatitis A , Hepatitis B Hepatitis C antibody Any antimalarial treatment past : piperaquinebased compound , mefloquine , naphthoquine sulphadoxine / pyrimethamine previous 6 week amodiaquine chloroquine previous 4 week quinine , halofantrine , lumefantrinebased compound antimalarial treatment antibiotic antimalarial activity ( include cotrimoxazole , tetracycline , quinolones fluoroquinolones , azithromycin ) past 14 day herbal product traditional medicine , past 7 day Have receive antibacterial treatment know antimalarial activity precede 14 day Have receive investigational drug 4 week prior screen ( ) Aspartate Aminotransferase / Alanine Aminotransferase least twice upper limit normal range total bilirubin normal ( b ) Aspartate Aminotransferase / Alanine Aminotransferase 1.5 time upper limit normal range total bilirubin great 1 less equal 1.5 time upper limit normal range Hemoglobin level less equal 8g/dL Total bilirubin great 1.5 time upper limit normal range Serum creatinine level twice upper limit normal range Female patient must neither lactate pregnant demonstrate negative pregnancy test screen predose must willing take measure become pregnant study period safety followup period ( abstinence oral contraceptive double barrier contraception , male condom , female condom diaphragm ) Any prohibited medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Plasmodium</keyword>
	<keyword>falciparum</keyword>
	<keyword>malaria</keyword>
	<keyword>vivax</keyword>
	<keyword>DSM265</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>adult</keyword>
</DOC>